Clinical Therapeutics
Volume 34, Issue 1 , Pages 239-249.e2 , January 2012

Prescription Drug Use in Pregnancy: A Retrospective, Population-Based Study in British Columbia, Canada (2001–2006)

The data in this article were presented in oral form at the Canadian Association for Health Services and Policy Research Annual Conference, Toronto, Ontario, Canada, May 10–13, 2010; and Innovations in Gender, Sex, and Health Research, Toronto, Ontario, Canada, November 22–23, 2010.

  • Jamie R. Daw, MSc

      Affiliations

    • Centre for Health Services and Policy Research, School of Population and Public Health, University of British Columbia, Vancouver, British Columbia, Canada
    • ,
  • Barbara Mintzes, PhD

      Affiliations

    • Centre for Health Services and Policy Research, School of Population and Public Health, University of British Columbia, Vancouver, British Columbia, Canada
    • Department of Anesthesiology, Pharmacology and Therapeutics, University of British Columbia, Vancouver, British Columbia, Canada
    • ,
  • Michael R. Law, PhD

      Affiliations

    • Centre for Health Services and Policy Research, School of Population and Public Health, University of British Columbia, Vancouver, British Columbia, Canada
    • ,
  • Gillian E. Hanley, PhD

      Affiliations

    • Centre for Health Services and Policy Research, School of Population and Public Health, University of British Columbia, Vancouver, British Columbia, Canada
    • ,
  • Steven G. Morgan, PhD

      Affiliations

    • Centre for Health Services and Policy Research, School of Population and Public Health, University of British Columbia, Vancouver, British Columbia, Canada
    • Corresponding Author InformationAddress correspondence to: Steven G. Morgan, PhD, Centre for Health Services and Policy Research, School of Population and Public Health, University of British Columbia, 201-2206 East Mall, Vancouver, BC, V6T1Z3, Canada

,Accepted 17 November 2011.

References 

  1. Frederiksen MC . The drug development process and the pregnant woman . J Midwifery Womens Health . 2002;47:422–425
  2. Daw JR , Hanley GE , Greyson DL , Morgan SG . Prescription drug use during pregnancy in developed countries: a systematic review . Pharmacoepidemiol Drug Saf . 2011;20:895–902
  3. Olesen C , Steffensen F , Nielsen G , et al.  Drug use in first pregnancy and lactation: a population-based survey among Danish women (The EUROMAP group) . Eur J Clin Pharmacol . 1999;55:139–144
  4. Malm H , Martikainen J , Klaukka T , Neuvonen PJ . Prescription drugs during pregnancy and lactation—a Finnish register-based study . Eur J Clin Pharmacol . 2003;59:127–133
  5. Lacroix I , Hurault C , Sarramon M , et al.  Prescription of drugs during pregnancy: a study using EFEMERIS, the new French database . Eur J Clin Pharmacol . 2009;65:839–846
  6. Egen-Lappe V , Hasford J . Drug prescription in pregnancy: analysis of a large statutory sickness fund population . Eur J Clin Pharmacol . 2004;60:659–666
  7. Garriguet D . Medication use among pregnant women . Health Rep . 2006;17:9–18
  8. Andrade S , Gurwitz J , Davis R , et al.  Prescription drug use in pregnancy . Am J Obstet Gynecol . 2004;191:398–407
  9. Riley E , Fuentes-Afflick E , Jackson R , et al.  Correlates of prescription drug use during pregnancy . J Womens Health . 2005;14:401–409
  10. Rubin J , Ferencz C , Loffredo C  Baltimore-Washington Infant Study Group . Use of prescription and non-prescription drugs in pregnancy . J Clin Epidemiol . 1993;46:581–589
  11. Kulaga S , Zargarzadeh A , Berard A . Prescriptions filled during pregnancy for drugs with the potential of fetal harm . Br J Obstet Gynecol . 2009;116:1788–1795
  12. Wen S , Yang T , Krewski D , et al.  Patterns of pregnancy exposure to prescription FDA C, D and X drugs in a Canadian population . J Perinatol . 2008;28:324–329
  13. Splinter M , Sagraves R , Nightengale B , Rayburn WF . Prenatal use of medications by women giving birth at a university hospital . Southern Med J . 1997;90:498–502
  14. Cooper W , Hickson G , Ray W . Prescriptions for contraindicated category X drugs in pregnancy among women enrolled in TennCare . Paediatr Perinatal Epidemiol . 2004;18:106–111
  15. World Health Organization . Anatomical Therapeutic Classification: Structure and Principles . http://www.whocc.no/atc/structure_and_principles/ Accessed January 15, 2010
  16. US Food and Drug Administration . Content and format of labeling for human prescription drug and biological products; requirements for pregnancy and lactation labeling . Fed Reg . 2008;73:30832–30833
  17. Wilson R . Principles of human teratology: drug, chemical and infectious exposure (SOGC Clinical Practice Guideline) . J Obstet Gynaecol Can . 2007;29:911–917
  18. Repchinsky CA . Drug use in pregnancy: resources and recommendations . Can Fam Physician . 2010;56:634
  19. Addis A , Sharabi S , Bonati M . Risk classification systems for drug use during pregnancy: are they a reliable source of information? . Drug Saf . 2000;23:245–253
  20. US Food and Drug Administration . Pregnancy and Lactation Labeling . http://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/Labeling/ucm093307.htm Accessed September 1, 2011
  21. Olesen C , Thrane N , Henriksen T , et al.  Associations between socio-economic factors and the use of prescription medication during pregnancy: a population-based study among 19,874 Danish women . Eur J Clin Pharmacol . 2006;62:547–553
  22. Gagne J , Maio V , Berghella V , et al.  Prescription drug use during pregnancy: a population-based study in Regione Emilia-Romagna, Italy . Eur J Clin Pharmacol . 2008;64:1125–1132
  23. Hansen W , Peacock A , Yankowitz J . Safe prescribing practices in pregnancy and lactation . J Midwifery Womens Health . 2002;47:409–421
  24. Schwarz EB , Postlethwaite DA , Hung YY , Armstrong MA . Documentation of contraception and pregnancy when prescribing potentially teratogenic medications for reproductive-age women . Ann Intern Med . 2007;147:370–376
  25. Calderon-Margalit R , Qiu C , Ornoy A , et al.  Risk of preterm delivery and other adverse perinatal outcomes in relation to maternal use of psychotropic medications during pregnancy . Am J Obstet Gynecol . 2009;201:e579
  26. Wikner BN , Stiller CO , Bergman U , et al.  Use of benzodiazepines and benzodiazepine receptor agonists during pregnancy: neonatal outcome and congenital malformations . Pharmacoepidemiol Drug Saf . 2007;16:1203–1210
  27. Briggs G , Freeman K , Yaffe S . In: Drugs in Pregnancy and Lactation . Philadelphia: Lippincott, Williams and Wilkins; 2008;
  28. Raebel M , Ellis J , Andrade S . Evaluation of gestational age and admission date assumptions used to determine prenatal drug exposure from administrative data . Pharmacoepidemiol Drug Saf . 2005;14:829–836
  29. Doering P , Boothby L , Cheok M . Review of pregnancy labeling of prescription drugs: is the current system adequate to inform of risks? . Am J Obstet Gynecol . 2002;187:333–339
  30. Sannerstedt R , Lundborg P , Danielsson B , et al.  Drugs during pregnancy: an issue of risk classification and information to prescribers . Drug Saf . 1996;14:69–77
  31. Feibus K . FDA's proposed rule for pregnancy and lactation labeling: improving maternal child health through well-informed medicine use . J Med Toxicol . 2008;4:284–288

PII: S0149-2918(11)00780-6

doi: 10.1016/j.clinthera.2011.11.025

Clinical Therapeutics
Volume 34, Issue 1 , Pages 239-249.e2 , January 2012

Article Tools

* Image Usage & Resolution